top glp-1 medications for weight loss 2025 Market Overview: Agonists and the Obesity Market | Blog GLP-1 Drugs for Weight Loss:

FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [press release]

GLP-1 Probiotic Pro is composed of commensal strains naturally found in the human gut

Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Compare this to the indefinite treatment paradigm of pharmaceutical GLP-1 medications, where the expectation is continuous use and discontinuation typically leads to rebound

More serious safety concerns include pancreatitis, gallbladder disease, and a potential risk of diabetic retinopathy complications with semaglutide

Clinical trials for CagriSema began in November 2022 and are projected to run through October 2026, with the drug administered under the skin once weekly